Consumer Staples Select Sector

S&P 500

The Balanced Allocator

Comparable Companies - CL

The insider data shows zero discretionary purchases and ten discretionary sales totaling $25,351,182.49. The latest short interest is 2.2% of float with a days‑to‑cover of 2.2. The top institutional holders are Vanguard Group Inc (10.47%), BlackRock, Inc. (8.79%), State Street Corp (6.05%), Price T Rowe Associates Inc /MD/ (3.89%) and Geode Capital Management, LLC (2.76%).

COO, EUR., APAC, AFR EUR, SKIN

CHIEF GROWTH OFFICER

EVP AND CONTROLLER

CHIEF HUMAN RESOURCES OFFICER

CHIEF FINANCIAL OFFICER

CLO AND SECRETARY

CHAIRMAN, PRESIDENT & CEO

Continues to lead the company following the 2025 Annual Meeting; no transition announced as of March 2026.

Chairman, President and Chief Executive Officer

Remains in role overseeing global financial operations and capital allocation strategies.

Chief Financial Officer

Verified as active via Form 4 filings in February 2026 regarding equity awards.

Chief Legal Officer and Secretary

Continues to oversee global innovation and category strategy.

Group President, Growth and Strategy

Maintains oversight of high-growth international regions.

Group President, Europe and Developing Markets

Continues service on the board following his departure from the CFO role at UPS in 2024.

Independent Director

Noel R. Wallace

Stanley J. Sutula III

Brian O. Newman

Martina Hund-Mejean

Noel Wallace represents the quintessential internal successor, having spent his entire professional career at Colgate-Palmolive. His provenance is defined by a deep operational understanding of global markets, particularly in Latin America and Eurasia. Since becoming CEO in 2019, he has successfully transitioned the company from a slow-growth staples giant to a more agile competitor in premium skin care and digital commerce. His capital allocation history reflects a disciplined approach, favoring bolt-on acquisitions that align with core competencies while maintaining a robust return of capital to shareholders through dividends and buybacks.

Acquisition of Laboratoires Filorga Cosmétiques

Divestiture of non-core laundry detergent brands in South Pacific

Stanley Sutula brings a rigorous, large-cap financial pedigree to Colgate, having served in senior leadership at IBM and as CFO of Pitney Bowes. His provenance is marked by expertise in navigating corporate transformations and managing complex balance sheets. At Colgate, he has acted as a 'Balanced Allocator,' successfully maintaining investment-grade credit ratings while executing a multi-billion dollar buyback program. His experience at Pitney Bowes, in particular, provides him with a unique perspective on managing legacy business declines while funding new growth engines.

Issuance of $2.9B in debt and execution of $4.8B in share buybacks

John T. Cahill

Steven A. Cahillane

Lisa M. Edwards

C. Martin Harris

Kimberly A. Nelson

Lorrie M. Norrington

Our business model is focused on delivering sustainable value creation by driving balanced top- and bottom-line growth. We create, manufacture, market and distribute a diversified portfolio of daily-use products to delight consumers with irresistible superiority across five key vectors - product performance, packaging, brand communication, retail execution and value.

Colgate-Palmolive operates approximately 85 U.S. properties (17 owned) and about 240 overseas properties (59 owned) in over 80 countries. Major U.S. manufacturing and warehousing sites are in Ohio, South Carolina and Tennessee for oral, personal and home care, and in Indiana, Kansas, Kentucky, Ohio and Oklahoma for pet nutrition. International facilities are located in Australia, Brazil, China, Colombia, France, Greece, Guatemala, India, Italy, Mexico, Poland, South Africa, Thailand, Turkiye and Vietnam, among others.

Colgate-Palmolive's financial story features modest 1.4% revenue growth to $20.4 billion amid 5-point operating margin drop to 16.2% from $919 million goodwill impairment, strong $4.2 billion operating cash flow at 197% conversion funding $4.8 billion buybacks over CapEx, yet eroding equity to $54 million and 14,793% debt/equity. The team excels in internal track record and board expertise but falters on alignment via insider sales and suboptimal buyback timing/M&A, rendering them adequate stewards for this Mature_Compounder needing per-share compounding amid balance sheet fragility.

The filing discusses material environmental regulation and compliance risks, including potential increased regulatory or legal scrutiny related to sustainability matters (e.g., responsible sourcing, deforestation, plastic use, energy and water), which could lead to fines, injunctions, product recalls, or adverse publicity. It notes the company is subject to extensive U.S. and foreign environmental rules and that compliance did not have a material adverse effect in 2025, but future compliance could impact capital expenditures, earnings, or competitive position. Legal proceedings related to environmental matters are also referenced.

As of December 31, 2025, the company had approximately 33,600 employees based in over 100 countries. Approximately 84% of employees are located outside the United States, with geographic distribution: 33% Asia Pacific, 31% Latin America, 17% North America, 15% Europe, and 4% Africa/Eurasia. A portion of employees are represented by unions.

The filing discusses extensive legal and regulatory requirements affecting product development, ingredients, formulation, manufacturing, packaging, labeling, and environmental impact. It notes risks from new or more stringent regulations (e.g., on ingredients like fluoride or PFAS), which could require product reformulation, restrict sales, or harm reputation. Product liability and consumer class action litigation risks are highlighted, along with the potential for product recalls or withdrawals if products are perceived as defective or unsafe.

The company discusses supply chain risks, including reliance on single-source suppliers for certain materials, which could require significant time and investment to qualify new suppliers. It mentions responsible sourcing as a stakeholder concern. Community initiatives are referenced, such as the 'Bright Smiles, Bright Futures' oral health education program and Hill's 'Food, Shelter & Love' program for pets.

The financial reality is modest top‑line growth of 1.4% YoY to $20.38 bn in FY2025, a 40 bps gross‑margin decline to 60.1%, a 5.0‑point operating‑margin drop to 16.2%, a $794 m goodwill impairment, and a negative tangible book of –$5.74 per share, leaving equity at only $54 m.

The Innovation Dossier and transcript describe SGPP as funding AI, omnichannel capabilities, and capacity‑expansion projects such as the Tonganoxie wet‑food facility, yet the CapEx line remained flat, indicating that most SGPP spend is classified as operating expense or internal cost‑saving rather than new plant construction.

The annual report and material events disclose $919 m goodwill impairment, $244 m intangible‑asset write‑down and $93 m customer‑relationship impairment in FY2025, all flagged as a Critical Audit Matter, indicating that the book value is heavily distorted by non‑cash write‑downs.

The Innovation Dossier cites capacity‑expansion projects (e.g., Tonganoxie wet‑food plant) and AI‑driven productivity as the main drivers of recent ROIC, yet the sharp decline in operating margin and the modest CapEx level ($564 m) suggest that the high incremental ROIC is largely a legacy effect of past high‑margin oral‑care assets rather than current reinvestment.

Colgate-Palmolive's capital structure in 2025 consists of a $3.0 billion revolving credit facility, $500 million of 4.20% Senior Notes due 2030, $147 million of 2.0% Commercial Paper due 2026, $2 million of notes and loans payable due 2026, $1,115 million of 2.9% Fixed-rate Notes due 2026, $523 million, $615 million, and $591 million of notes due 2027, 2028, and 2029, respectively, and $4,495 million of other long-term notes. Total debt outstanding is $7,988 million, with approximately 15.82% due in the next year and 43.73% due within five years. The company reports full compliance with all financial covenants attached to its revolving credit facility, though specific covenant thresholds are not disclosed. The facility provides a backstop for commercial paper and carries no material commitment fees. Overall, the debt profile reflects a balanced mix of short-term liquidity tools and longer-term fixed-rate obligations, supporting the company's ongoing capital-structure objectives while maintaining ample liquidity and covenant compliance.

Revolving Credit Facility (amended $3,000 million five-year facility, extended to 2030)

Senior Notes issued April 2025 (5-year, $500 million)

P/FCF

EV/EBITDA

Jennifer M. Daniels

John P. Bilbrey

The Vanguard Group

BlackRock, Inc.

State Street Corporation

Hazlin John

Daniels Jennifer

Malcolm Gregory

Massey Sally

Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2025

Stockholder proposal entitled 'Support an independent Board Chairman'

Stockholder proposal entitled 'Revisit plastic packaging policies'

Bilbrey

Not Disclosed

Prabha Parameswaran

Panagiotis Tsourapas

Colgate-Palmolive Company is a caring, innovative growth company founded in 1806 and incorporated in Delaware in 1923. It markets consumer products in over 200 countries and territories, organized into two product segments - Oral, Personal and Home Care and Pet Nutrition. The Oral, Personal and Home Care segment includes toothpaste, toothbrushes, mouthwashes, hand soaps, bar soaps, shower gels, deodorants, skin-health products, dishwashing liquids, household cleaners and fabric conditioners. The Pet Nutrition segment provides pet food and related products.

Held WACC at 9.0% and base case terminal multiple at 18.0x constant, solved for Year 5 margin to justify current price of 93.56.

Balance Sheet - Supplemental

Balance Sheet

Cash Flow Statement - Supplemental

Cash Flow Statement

Income Statement - Supplemental

Income Statement

Ratios

Valuation

Historical Ratios & Multiples - CL

The consumer staples sector is facing a K-shaped recovery. While premiumization and science-based innovation drive growth in pet nutrition and e-commerce, legacy categories in North America are struggling with consumer uncertainty and inventory destocking. Colgate is outperforming in European toothpaste share but underperforming in U.S. volume growth, where it faces a 1.0% decline.

Colgate-Palmolive is relevant now because the recent 794 million USD impairment and the collapse of equity to 54 million USD mark a fundamental turning point in the company's financial health that the market has yet to fully price.

Strategic Growth and Productivity Program (SGPP) Execution Successful realization of 200-300 million USD in cost savings could temporarily boost margins and sentiment.

Hill's Pet Nutrition Outperformance Continued organic growth exceeding 5% in the therapeutic segment validates the only remaining high-growth engine.

Moat Erosion and Volume Decline Permanent loss of market share in North America to private labels or more agile competitors impairs pricing power.

Tariff and Inflationary Pressure Incremental costs from new tariffs (estimated at 200 million USD) and raw material inflation compress margins further.

Stewardship is currently focused on maintaining the 'Compounder' image at the expense of balance sheet health. Outcome Tree: 1. Status Quo: Management executes SGPP, margins stabilize at 18%, and the stock remains range-bound as buybacks continue. 2. Compromise: The Board faces pressure to halt buybacks to repair the balance sheet, leading to a short-term multiple de-rating. 3. Reset: Continued volume declines for...

Liquidation value analysis is not relevant for the company's archetype ('Mature_Compounder') and was not performed.

Colgate-Palmolive reports Q4 and full year 2025 results with goodwill impairment charges impacting earnings

Colgate-Palmolive reports Q4 and full year 2022 results with goodwill impairment charges impacting earnings

Market/Sector Move -5.13%

Colgate-Palmolive price target raised to $100 from $94 at Goldman Sachs

Colgate-Palmolive target raised to $93 from $84 at Rothschild & Co Redburn

Colgate-Palmolive price target raised to $88 from $83 at Barclays

Colgate-Palmolive price target raised to $100 from $87 at Morgan Stanley

Colgate-Palmolive price target raised to $94 from $86 at Wells Fargo

Colgate-Palmolive price target raised to $96 from $88 at Piper Sandler

Colgate-Palmolive price target raised to $93 from $90 at UBS

Colgate-Palmolive price target lowered to $85 from $86 at Jefferies

Colgate-Palmolive upgraded to Outperform from Sector Perform at RBC Capital

Colgate-Palmolive price target lowered to $86 from $94 at Deutsche Bank

Colgate-Palmolive price target raised to $94 from $91 at Goldman Sachs

Colgate-Palmolive price target raised to $83 from $80 at Barclays

Colgate-Palmolive upgraded to Equal Weight from Underweight at Wells Fargo

Piper upgrades Colgate-Palmolive on potential 2026 growth acceleration

Colgate-Palmolive price target lowered to $87 from $96 at Morgan Stanley

Colgate-Palmolive price target lowered to $92 from $99 at UBS

Colgate-Palmolive assumed with a Neutral at Piper Sandler

Colgate-Palmolive price target lowered to $82 from $87 at Barclays

Situation: Current price is $93.56 versus fair value $77.55 (-17.1% expected return), and valuation confidence is stable. Debate: Bull case depends on Strategic Growth and Productivity Program (SGPP) Execution Successful realization of 200-300 million USD in cost savings could temporarily boost margins and sentiment. Bear case centers on Moat Erosion and Volume Decline Permanent loss of market share in North America to private labels or more agile competitors impairs pricing power. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.

Executive Summary

Colgate-Palmolive is transitioning from a high-quality compounder to a low-growth legacy business with a hollowed-out balance sheet. While cash flow remains robust, the erosion of equity to 54 million USD and a negative tangible book value of 5.74 USD per share create a fragile capital structure that no longer justifies a premium valuation multiple.<ul><li>Driver: Structural margin compression and balance sheet fragility.</li><li>Catalyst: Continued volume weakness in North America and a 200 million USD incremental tariff impact.</li><li>Protection: Strong 4.2 billion USD operating cash flow providing a temporary buffer for debt service.</li></ul>Our variant perception is based on time arbitrage. The market is pricing the stock for a 'fade to average' over the next 3-5 years, whereas our analysis of the brand moat suggests the company has already transitioned to a lower-return regime that no longer justifies its historical premium. Specifically, the market is ignoring the fact that 60% of recent buybacks were effectively debt-funded as equity eroded to near-zero levels following 919 million USD in total impairments in FY2025.This is a mean-reversion trade predicated on the market eventually re-rating the stock downward as the reality of structural growth deceleration and balance sheet fragility becomes undeniable.

Core Investment Rationale

Colgate-Palmolive operates as a global consumer staples giant focused on Oral Care, Personal Care, Home Care, and Pet Nutrition. The company generates 20.38 billion USD in annual revenue, with approximately 70% of sales originating outside the United States. Strategy is currently centered on the 2030 Strategic Growth and Productivity Program (SGPP), which aims to leverage AI-driven capabilities and innovation to restore organic growth to a 1-4% range. However, the business model is currently under pressure from North American volume declines of 1.0% and raw material inflation in fats and oils.The company's moat is anchored in its global brand portfolio, including the flagship Colgate toothpaste, which maintains a 38.1% value share in Europe, and Hill's Pet Nutrition, which continues to deliver organic growth exceeding 5%. Core assets are primarily intangible, with trademarks and brand equity forming the basis of its pricing power. Physical assets include 325 properties worldwide, with major manufacturing hubs in the U.S., Brazil, China, and Mexico. Notably, the skin health unit (Filorga) has seen its asset value impaired by 794 million USD due to persistent weakness in the China market.The industry is a rational oligopoly dominated by Procter & Gamble, Unilever, and Kimberly-Clark. Colgate-Palmolive holds a unique position with a 60.1% gross margin, which is 20.0 percentage points higher than the peer median of 40.1%. Despite this, the company is losing ground in North America, where promotional intensity is rising and private-label exits have removed low-margin volume but failed to spark a broader recovery.Colgate-Palmolive has a history of consistent execution, evidenced by 63 consecutive years of dividend increases and a 5-year average ROIC of 25.5%. However, the current situation is defined by a pivot toward high-margin skin care that has faltered, resulting in a 919 million USD total impairment in FY2025 and a collapse of the equity base from 609 million USD in 2021 to just 54 million USD today. Management has attempted to mask this deterioration through aggressive share buybacks totaling 4.8 billion USD over the last five years, but these have been largely debt-funded, pushing the debt-to-equity ratio to an extreme 14,793%.

Business & Situation

<ul><li>Bull Case: Hill's Pet Nutrition remains a high-growth engine with >5% organic growth; Emerging market pricing power (0.6% price lift) offsets developed market volume weakness.</li><li>Bear Case: Balance sheet is hollowed out with negative 4.6 billion USD tangible book value; Operating margins have collapsed 500 basis points to 16.2% due to impairments and inflation.</li></ul>The consensus view is that Colgate-Palmolive is a 'safe haven' compounder with a fortress brand that can weather any macro storm. Investors point to the 100% quarterly EPS hit rate and the 5.9% price jump following the Q4 2025 earnings release as evidence of resilience, choosing to look past the 'non-cash' impairment charges. This narrative is supported by the company's ability to generate 4.2 billion USD in operating cash flow, which represents 197% of net income, allowing for continued dividend growth and buybacks.The consumer staples sector is facing a K-shaped recovery. While premiumization and science-based innovation drive growth in pet nutrition and e-commerce, legacy categories in North America are struggling with consumer uncertainty and inventory destocking. Colgate is outperforming in European toothpaste share but underperforming in U.S. volume growth, where it faces a 1.0% decline.The market is overly focused on short-term pricing gains in emerging markets while underappreciating the durability of the balance sheet erosion. Our differentiated view is that the negative tangible book value of 4.6 billion USD and the 14,793% debt-to-equity ratio create a fragility that the market's 21.3x EV/EBITDA multiple ignores. This multiple represents a 48% premium to the peer median of 14.4x, which is unjustified given that operating margins have fallen to 16.2%, barely above the peer median of 15.1%. The governance friction created by massive insider selling-25.4 million USD in the last 12 months with zero purchases-suggests that those closest to the business do not share the market's optimism.The debate centers on whether CL is a premium compounder or a legacy business in decline. The evidence of a 5.0-point operating margin drop and a near-zero equity base suggests the latter. The current valuation is a relic of past performance, not a reflection of future reality.Our analytical edge comes from a deeper appreciation of the company's hollowing balance sheet. While the market sees a stable cash-flow engine, our analysis of the capital cycle suggests that the company is over-investing in a peak cycle (2.8% capex intensity vs 1.4% revenue growth) while returning capital it doesn't truly have in equity form. We have identified that 60% of buybacks are effectively debt-funded, a unsustainable strategy for a Mature_Compounder.

Core Thesis

CEO Noel Wallace is a 30-year veteran who successfully accelerated organic sales to the 3-5% range as COO. However, his tenure as CEO has been marked by the 1.7 billion USD Filorga acquisition, which has now been largely impaired, and a failure to stabilize North American volumes. There is no active proxy fight, but the massive insider selling by Wallace (4.3 million USD) and CFO Sutula (9.2 million USD) in early 2026 suggests a lack of alignment with long-term shareholders.Adequate but declining. While the team has delivered a 19.7% net yield through buybacks and dividends, the timing has been poor. 2025 buybacks were executed at an average price of 78.39 USD when the EV/EBITDA multiple was 22.1x, and M&A effectiveness is calculated at -0.5x on 1.1 billion USD of spend.Management maintains a consistent narrative in transcripts, but their guidance hit rate is poor. Annual revenue targets have been hit only 40% of the time over the last five years, and annual EPS targets have missed 100% of the time, indicating a tendency toward over-optimism.<ul><li>Board Independence: 86% (6 of 7 directors)</li><li>Chairman/CEO Roles: Combined (Noel Wallace)</li><li>Chairman Tenure: 7 years</li><li>Insider Ownership: 0.09%</li><li>Shareholder Rights: Majority Vote Standard, Proxy Access, 15% Special Meeting Threshold</li></ul>Stewardship is currently focused on maintaining the 'Compounder' image at the expense of balance sheet health. Outcome Tree: 1. Status Quo: Management executes SGPP, margins stabilize at 18%, and the stock remains range-bound as buybacks continue. 2. Compromise: The Board faces pressure to halt buybacks to repair the balance sheet, leading to a short-term multiple de-rating. 3. Reset: Continued volume declines force a strategic review of the skin health unit, potentially leading to a divestiture and a valuation reset toward the 77.55 USD fair value.

Leadership & Governance

The valuation floor is anchored to the Bear Case DCF value of 55.31 USD, which models a permanent erosion of the company's moat and margin compression to 14.0% by Year 5.Base case assumes 3.0% revenue growth and margins stabilizing at 18.0% as SGPP cost savings offset tariff headwinds. Implied value: 77.79 USD.Bull case assumes Hill's growth exceeds 5% and European share gains continue, driving margins to 20.0%. Blue-Sky Potential: 93.03 USD.The Bear Case is defined by a scenario of moat erosion and declining profitability. The final Bear Case value of 55.31 USD is determined directly by the Bear Case DCF scenario, assuming 1.0% revenue growth and 14.0% margins.

Valuation Context

<ul><li>Strategic Growth and Productivity Program (SGPP) Execution Successful realization of 200-300 million USD in cost savings could temporarily boost margins and sentiment.</li><li>Hill's Pet Nutrition Outperformance Continued organic growth exceeding 5% in the therapeutic segment validates the only remaining high-growth engine.</li><li>Colgate-Palmolive is relevant now because the recent 794 million USD impairment and the collapse of equity to 54 million USD mark a fundamental turning point in the company's financial health that the market has yet to fully price.</li></ul>Colgate-Palmolive is relevant now because the recent 794 million USD impairment and the collapse of equity to 54 million USD mark a fundamental turning point in the company's financial health that the market has yet to fully price.

Catalyst Path & Context

<ul><li>Moat Erosion and Volume Decline Permanent loss of market share in North America to private labels or more agile competitors impairs pricing power. North American volumes declined 1.0% in FY2025 despite increased advertising spend.</li><li>Tariff and Inflationary Pressure Incremental costs from new tariffs (estimated at 200 million USD) and raw material inflation compress margins further. Gross margins already slipped 40 basis points to 60.1% in FY2025.</li><li>Stewardship is currently focused on maintaining the 'Compounder' image at the expense of balance sheet health. Outcome Tree: 1. Status Quo: Management executes SGPP, margins stabilize at 18%, and the stock remains range-bound as buybacks continue. 2. Compromise: The Board faces pressure to halt buybacks to repair the balance sheet, leading to a short-term multiple de-rating. 3. Reset: Continued volume declines for... Risk monitor: Current price $93.56 vs fair value $77.55, expected return -17.1%.</li></ul>

Primary Risks

<ul><li>Entry Target: No new entries: recommendation is Sell.</li><li>Stop Loss: No stop-loss needed because recommendation is Sell (no position).</li><li>Position Size: Position size is None under current recommendation and risk constraints.</li><li>Time Horizon: N/A for a Sell recommendation.</li></ul><ul><li>Management announced SGPP in the Q4 2025 earnings call to fund the 2030 strategy.</li><li>Hill's volume growth is currently driven by therapeutic and prescription diet gains.</li><li>North American volumes declined 1.0% in FY2025 despite increased advertising spend.</li></ul>The 'killer' is a successful execution of the SGPP that restores operating margins to the 20% level while North American volumes return to positive growth, proving the moat's resilience. Also require valuation reliability to improve before re-entering.

Actionable Parameters & Monitoring

CL appears overvalued (fair value $77.55 vs current $93.56, expected return -17.1%). Recommendation: Sell; do not allocate until valuation and risk profile reset.

Final Conclusion

Structural margin compression and balance sheet fragility.

Driver

Continued volume weakness in North America and a 200 million USD incremental tariff impact.

Catalyst

Strong 4.2 billion USD operating cash flow providing a temporary buffer for debt service.

Protection

Hill's Pet Nutrition remains a high-growth engine with >5% organic growth; Emerging market pricing power (0.6% price lift) offsets developed market volume weakness.

Bull Case

Balance sheet is hollowed out with negative 4.6 billion USD tangible book value; Operating margins have collapsed 500 basis points to 16.2% due to impairments and inflation.

Bear Case

Situation: Current price is $93.56 versus fair value $77.55 (-17.1% expected return), and valuation confidence is stable. Debate: Bull case depends on Strategic Growth and Productivity Program (SGPP) Execution Successful realization of 200-300 million USD in cost savings could temporarily boost margins and sentiment. Bear case centers on Moat Erosion and Volume Decline Permanent loss of market share in North America to private labels or more agile competitors impairs pricing power. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.

The strategy evolved from a focus on balanced organic growth through innovation, advertising, and revenue growth management (RGM 2.0) in FY2024 to a major organizational pivot in FY2025. The FY2025 pivot centers on a new 2030 strategy with five pillars and the multi-year Strategic Growth and Productivity Program (SGPP) to restructure the organization, fund new capabilities (AI, omnichannel), and drive productivity, marking a shift from execution-focused growth to structural transformation for long-term competitiveness.

Method	Implied Value	Weight	Weighted Value
DCF	$77.87	50%	$38.94
Comps	$77.22	30%	$23.17
Historicals	$77.22	20%	$15.44
Total Weighted			$77.55

CL

Company Overview

Price History